Spexis AG
SIX:SPEX

Watchlist Manager
Spexis AG Logo
Spexis AG
SIX:SPEX
Watchlist
Price: 0.01 CHF -75% Market Closed
Market Cap: 3.9m CHF

Relative Value

There is not enough data to reliably calculate the relative value of SPEX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SPEX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
Forward
1.7
vs History
vs Industry
Median 3Y
-1.1
Median 5Y
-8.5
Industry
23.5
Forward
-0.2
vs History
vs Industry
Median 3Y
-3.7
Median 5Y
-8.3
Industry
21.9
vs History
vs Industry
Median 3Y
-11.8
Median 5Y
-18
Industry
24.3
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.2
Industry
3.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
Forward
4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-9.3
Industry
5.9
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-8.6
Industry
6.2
Forward
-0.3
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-9.1
Industry
7.7
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-9.1
Industry
6.3
vs History
vs Industry
Median 3Y
1.9
Median 5Y
5.6
Industry
5.6

Multiples Across Competitors

SPEX Competitors Multiples
Spexis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Spexis AG
SIX:SPEX
3.9m CHF 0 -0.2 -0.5 -0.4
IL
Can Fite Biopharma Ltd
TASE:CANF
707T ILS 256 368 717.6 -17 605 753.9 -17 276 635.9 -17 238 178.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 103 527.5 -162 089 -196 827.8 -194 581.7
US
Abbvie Inc
NYSE:ABBV
390.6B USD 6.5 166.4 16.2 22.9
US
Amgen Inc
NASDAQ:AMGN
176.9B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
150.3B USD 5.2 18.5 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.8B USD 10.2 32.6 24 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.7 -527.1 -574 -558.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
84.2B USD 5.9 18.4 17.6 19.9
AU
CSL Ltd
ASX:CSL
84.4B AUD 3.6 18.8 12.7 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
53.6B USD 16.7 1 229.6 165.8 201.1
P/S Multiple
Revenue Growth P/S to Growth
CH
Spexis AG
SIX:SPEX
Average P/S: 29 047 436.4
Not Available
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
256 368 717.6
140%
1 831 205.1
FR
Pharnext SCA
OTC:PNEXF
34 103 527.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 065.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.9
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.7
46%
0.4
P/E Multiple
Earnings Growth PEG
CH
Spexis AG
SIX:SPEX
Average P/E: 215.7
Negative Multiple: -0.2
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 605 753.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 089 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.4
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.5
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
10%
1.8
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 229.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Spexis AG
SIX:SPEX
Average EV/EBITDA: 38.1
Negative Multiple: -0.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 276 635.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 827.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Spexis AG
SIX:SPEX
Average EV/EBIT: 45.1
Negative Multiple: -0.4
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -17 238 178.6 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 581.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
201.1
N/A N/A